Subject(s)
COVID-19 Testing/methods , COVID-19/diagnosis , SARS-CoV-2/pathogenicity , Antibodies, Monoclonal/biosynthesis , Antibodies, Viral/biosynthesis , COVID-19/therapy , COVID-19/virology , COVID-19 Testing/instrumentation , COVID-19 Testing/standards , Clinical Trials as Topic , Humans , Point-of-Care Testing/organization & administration , SARS-CoV-2/genetics , SARS-CoV-2/immunologyABSTRACT
The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA on 1-5 April 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event - a full immersion week of bioanalysis, biomarkers, immunogenicity and gene therapy. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule bioanalysis involving LCMS, hybrid LBA/LCMS, LBA cell-based/flow cytometry assays and qPCR approaches. This 2019 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2019 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 2) covers the recommendations on the 2018 FDA BMV guidance, 2019 ICH M10 BMV draft guideline and regulatory agencies' input on bioanalysis, biomarkers, immunogenicity and gene therapy. Part 1 (Innovation in small molecules and oligonucleotides and mass spectrometry method development strategies for large molecules bioanalysis) and Part 3 (New insights in biomarker assay validation, current and effective strategies for critical reagent management, flow cytometry validation in drug discovery and development and CLSI H62, interpretation of the 2019 FDA immunogenicity guidance and gene therapy bioanalytical challenges) are published in volume 10 of Bioanalysis, issues 22 and 24 (2019), respectively.
Subject(s)
Biological Assay/standards , Biomarkers/analysis , Guidelines as Topic , Immunogenetic Phenomena , Research Report , United States Food and Drug Administration/legislation & jurisprudence , Humans , United StatesABSTRACT
The 13th GCC Closed Forum for Bioanalysis was held in New Orleans, Louisiana, USA on April 5th, 2019. This GCC meeting was organized to discuss the contents of the 2019 ICH M10 Bioanalytical Method Validation Draft Guideline published in February 2019 and consolidate the feedback of the GCC members. In attendance were 63 senior-level participants from eight countries representing 44 bioanalytical CRO companies/sites. This event represented a unique opportunity for CRO bioanalytical experts to share their opinions and concerns regarding the ICH M10 Bioanalytical Method Validation Draft Guideline and to build unified comments to be provided to the ICH.
Subject(s)
Biomarkers/analysis , Guidelines as Topic , Humans , Reproducibility of Results , Research DesignABSTRACT
The 12th GCC Closed Forum was held in Philadelphia, PA, USA, on 9 April 2018. Representatives from international bioanalytical Contract Research Organizations were in attendance in order to discuss scientific and regulatory issues specific to bioanalysis. The issues discussed at the meeting included: critical reagents; oligonucleotides; certificates of analysis; method transfer; high resolution mass spectrometry; flow cytometry; recent regulatory findings and case studies involving stability and nonclinical immunogenicity. Conclusions and consensus from discussions of these topics are included in this article.
Subject(s)
Certification , Chemistry Techniques, Analytical , Flow Cytometry , Mass Spectrometry , Oligonucleotides/analysis , Social Control, Formal , Societies, Scientific , Indicators and Reagents/chemistryABSTRACT
Biography Chad received his Bachelor of Science degree in Chemistry from Alma College in Michigan and a Master's degree in Analytical Chemistry from the University of Michigan with a focus in the use of LC-MS/MS in protein and peptide analysis. Chad's Doctorate of Philosophy at the University of Nebraska was focused on studies of protein binding via affinity LC-MS/MS and computer simulations. Chad's career of nearly 25 years includes positions of increasing responsibility ranging from bench scientist to his current role as global head of scientific affairs for Bioanalytical Science at PRA. He is a frequently invited speaker at global scientific meetings in the field of Bioanalytical Laboratory Science including WRIB, AAPS, CPSA and Land O'Lakes Bioanalysis. He is on the organizational committee and has chaired several meetings as well including the Land O'Lakes Bioanalytical Meeting and the CPSA Meeting and the upcoming AAPS meeting on cellular and gene therapy. He is also a Bioanalysis Zone leader.
Subject(s)
Career Choice , Chemistry, Analytic , Gender Identity , Career Mobility , Humans , Industry , Research Personnel/psychologyABSTRACT
The 11th Global CRO Council Closed Forum was held in Universal City, CA, USA on 3 April 2017. Representatives from international CRO members offering bioanalytical services were in attendance in order to discuss scientific and regulatory issues specific to bioanalysis. The second CRO-Pharma Scientific Interchange Meeting was held on 7 April 2017, which included Pharma representatives' sharing perspectives on the topics discussed earlier in the week with the CRO members. The issues discussed at the meetings included cumulative stability evaluations, matrix stability evaluations, the 2016 US FDA Immunogenicity Guidance and recent and unexpected FDA Form 483s on immunogenicity assays, the bioanalytical laboratory's role in writing PK sample collection instructions, biosimilars, CRO perspectives on the use of chiral versus achiral methods, hybrid LBA/LCMS assays, applications of fit-for-purpose validation and, at the Global CRO Council Closed Forum only, the status and trend of current regulated bioanalytical practice in China under CFDA's new BMV policy. Conclusions from discussions of these topics at both meetings are included in this report.
Subject(s)
Biological Assay/methods , Biomarkers/analysis , Biosimilar Pharmaceuticals/therapeutic use , China , Humans , Research DesignABSTRACT
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California from 3 April 2017 to 7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, weeklong event - A Full Immersion Week of Bioanalysis, Biomarkers and Immunogenicity. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small and large molecule analysis involving LCMS, hybrid LBA/LCMS and ligand-binding assay (LBA) approaches. This 2017 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2017 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1) covers the recommendations for Small Molecules, Peptides and Small Molecule Biomarkers using LCMS. Part 2 (Biotherapeutics, Biomarkers and Immunogenicity Assays using Hybrid LBA/LCMS and Regulatory Agencies' Inputs) and Part 3 (LBA: Immunogenicity, Biomarkers and PK Assays) are published in volume 9 of Bioanalysis, issues 23 and 24 (2017), respectively.
Subject(s)
Biomarkers/analysis , Chromatography, High Pressure Liquid , Mass Spectrometry , Peptides/analysis , Small Molecule Libraries/analysis , Consensus Development Conferences as Topic , Guidelines as Topic , Ligands , Small Molecule Libraries/chemistryABSTRACT
The 2016 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) took place in Orlando, Florida with participation of close to 700 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations, and regulatory agencies worldwide. WRIB was once again a 5-day, weeklong event - A Full Immersion Week of Bioanalysis including Biomarkers and Immunogenicity. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small and large molecule analysis involving LCMS, hybrid LBA/LCMS, and LBA approaches, with the focus on biomarkers and immunogenicity. This 2016 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. This white paper is published in 3 parts due to length. This part (Part 1) discusses the recommendations for small molecules, peptides and small molecule biomarkers by LCMS. Part 2 (Hybrid LBA/LCMS and regulatory inputs from major global health authorities) and Part 3 (large molecule bioanalysis using LBA, biomarkers and immunogenicity) will be published in the Bioanalysis journal, issue 23.
ABSTRACT
The 9th GCCClosed Forum was held just prior to the 2015 Workshop on Recent Issues in Bioanalysis (WRIB) in Miami, FL, USA on 13 April 2015. In attendance were 58 senior-level participants, from eight countries, representing 38 CRO companies offering bioanalytical services. The objective of this meeting was for CRO bioanalytical representatives to meet and discuss scientific and regulatory issues specific to bioanalysis. The issues selected at this year's closed forum include CAPA, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, and ELNs. A summary of the industry's best practices and the conclusions from the discussion of these topics is included in this meeting report.
Subject(s)
Biomarkers/analysis , Biosimilar Pharmaceuticals/analysis , Drug Evaluation, Preclinical/methods , Biomarkers/blood , Electronic Health Records , Laboratories , Societies, Medical , Validation Studies as TopicABSTRACT
The 8th GCC Closed Forum for Bioanalysis was held in Baltimore, MD, USA on 5 December 2013, immediately following the 2013 AAPS Workshop (Crystal City V): Quantitative Bioanalytical Methods Validation and Implementation--The 2013 Revised FDA Guidance. This GCC meeting was organized to discuss the contents of the draft revised FDA Guidance on bioanalytical method validation that was published in September 2013 and consolidate the feedback of the GCC members. In attendance were 63 senior-level participants, from seven countries, representing 46 bioanalytical CRO companies/sites. This event represented a unique opportunity for CRO bioanalytical experts to share their opinions and concerns regarding the draft FDA Guidance, and to build unified comments to be provided to the FDA.
Subject(s)
Chemistry Techniques, Analytical/standards , Guidelines as Topic , Validation Studies as Topic , Biomarkers/analysis , Calibration , Ligands , Limit of Detection , Reagent Kits, Diagnostic , Reproducibility of Results , United States , United States Food and Drug AdministrationABSTRACT
The University of Wisconsin bioanalytical conference is presented each year by the Extension Services in Pharmacy, the professional development department within the School of Pharmacy. The purpose of this 3-day conference was to provide an educational forum to discuss issues and applications associated with the analysis of xenobiotics, metabolites, biologics and biomarkers in biological matrices. The conference was designed to include and encourage an open exchange of scientific and methodological applications for bioanalysis. To increase the interactive nature of the conference the program was composed of a mixture of lectures, interactive discussions, poster sessions and roundtables. This paper summarizes the presentations at the Fourteenth Annual Conference, offered in a new venue.
Subject(s)
Biological Products/analysis , Xenobiotics/analysis , Biomarkers/analysis , Chemistry, Analytic , HumansABSTRACT
Bioanalysis invited a selection of leading researchers to express their views on increasing and maintaining productivity in the bioanalytical laboratory. The topics discussed include the challenges of maintaining productivity when integrating new innovations into existing processes, the impact of automation on productivity, and how they effectively manage productivity in their own bioanalytical laboratories. Their enlightening responses provide a valuable insight into current methods of increasing productivity and the future of the constantly evolving bioanalytical laboratory.
Subject(s)
Chemistry Techniques, Analytical , Efficiency, Organizational , Efficiency , Drug Design , Laboratories/organization & administrationABSTRACT
The Applied Pharmaceutical Software Meeting is held annually. It is sponsored by The Boston Society, a not-for-profit organization that coordinates a series of meetings within the global pharmaceutical industry. The meeting generally focuses on laboratory applications, but in recent years has expanded to include some software applications for clinical trials. The 2011 meeting emphasized the global laboratory environment. Global clinical trials generate massive amounts of data in many locations that must be centralized and processed for efficient analysis. Thus, the meeting had a strong focus on establishing networks and systems for dealing with the computer infrastructure to support such environments. In addition to the globally installed laboratory information management system, electronic laboratory notebook and other traditional laboratory applications, cloud computing is quickly becoming the answer to provide efficient, inexpensive options for managing the large volumes of data and computing power, and thus it served as a central theme for the meeting.
Subject(s)
Clinical Trials as Topic , Database Management Systems , Drug Industry/standards , Laboratories , Biomedical Research , Clinical Trials as Topic/standards , Database Management Systems/organization & administration , Database Management Systems/standards , Database Management Systems/trends , Drug Industry/methods , Drug Industry/trends , Information Dissemination , Internationality , Laboratories/standards , United StatesABSTRACT
This University of Wisconsin School of Pharmacy bioanalytical conference is presented each year by the Extension Services in Pharmacy, the professional development department within the school. The purpose of this 4-day conference is to provide an educational forum to discuss issues and applications associated with the analysis of xenobiotics, metabolites, biologics and biomarkers in biological matrices. The conference is designed to include and encourage an open exchange of scientific and methodological applications for bioanalysis. To increase the interactive nature of the conference, the program was a mixture of lectures, poster sessions, round table discussions and workshops. This article summarizes the presentations at the 12th Annual Conference.